Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Repligen Corp.
News that the Australian biotech's paxalisib did not meet pre-defined criteria to continue into the second stage of a major glioblastoma platform trial saw Kazia's stock crash, but investor reaction appears to be excessive.
The small-cap biotech is not currently favored by investors but CEO Anat Cohen-Dayag tells Scrip she believes Compugen could have the optimal TIGIT strategy.
Biosimilar licensing agreement also includes option on Yervoy-based product. Oxford BioTherapeutics, ImmunoGen pair their technologies for development of novel cancer ADCs.
French pharma makes $180m equity investment in Owkin under collaboration targeting four cancer types. Pyramid gets global license to MPS1 precision cancer candidate from Voronoi.
- Research, Analytical Equipment & Supplies
- Synthesis Technologies, Production Processes
- Other Names / Subsidiaries
- Atoll GmBH
- Avitide, Inc.
- Bio-Flex Solutions LLC
- C Technologies, Inc.
- Newton T&M Corp.
- Novozymes Biopharma Sweden AB
- TangenX Technology Corporation
- Polymem S.A.